The Blue Box has developed a urine-based breast cancer screening device that operates without radiation and is designed to be pain-free and low-cost, achieving a sensitivity of 88.42%. This technology addresses the lack of reliable screening methods for women, particularly those under 50, who are often diagnosed at late stages of breast cancer.
Funding
$541K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current breast cancer screening methods, like mammography, are often unreliable for women under 50, particularly those with dense breast tissue, leading to late-stage diagnoses. Existing screening options can also be painful, involve radiation exposure, and require frequent clinic visits, deterring regular check-ups.
Solution
The Blue Box is developing a urine-based breast cancer screening device that offers a pain-free, radiation-free, and low-cost alternative to traditional methods. The device utilizes chemical analysis and artificial intelligence to detect breast cancer biomarkers in urine samples, achieving a high degree of sensitivity. Results are sent to a secure cloud platform, where AI algorithms analyze the data and provide a diagnosis via a mobile app. This non-invasive approach aims to increase screening accessibility and frequency, especially for women who may not have reliable screening methods available.
Target Audience
The primary target audience includes women aged 20-49, particularly those with dense breast tissue, as well as gynecology clinics offering breast cancer screening services.
Features
- Non-invasive breast cancer screening using urine samples
- AI-powered analysis for high-accuracy detection
- Radiation-free and pain-free testing process
- Mobile app for receiving test results and tracking history
- Cloud-based platform for secure data storage and analysis
- High sensitivity compared to mammography for women under 50
- Diagnostics-as-a-Service subscription model for gynecology clinics (planned)